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INTRODUCTION 
Nanotechnology is defined as the production and 
application of materials at nanometer scale. It involves 
the study of control of matter on an atomic and 
molecular scale which is usually below 100 nm or in the 
range of 0.2 nm to 100 nm1. In simple terms, it is one 
billionth of a meter i.e., 10-9 meters2. The primary goals 
for research in nanotechnology include: 
 Specific and targeted drug delivery 
 Decreased toxicity and maintenance of therapeutic 
effects 
 Increased safety and biocompatibility 
 Faster development of new and safer medicines3 
The active pharmaceutical ingredient and its release 
mechanism from drug delivery system plays a critical 
role in determining the safety and efficacy of 
therapeutics4. The active pharmaceutical ingredient in 
nanoparticulate drug delivery system is either dissolved, 
entrapped, encapsulated or attached to a matrix and 
depending on this nanoparticles, nanospheres or 
nanocapsules may be obtained5. 
 Nanoparticles are solid colloidal particles consisting 
of macromolecular substances that vary in size from 
10-1000 nm. 
 Nanospheres are matrix systems in which the drug is 
physically and uniformly dispersed. 
 Nanocapsules are vesicular systems in which a drug 
is confined to a cavity surrounded by a polymer 
membrane6. 
Large size materials in drug delivery systems pose 
problems such as poor bioavailability, solubility, 
intestinal absorption, plasma fluctuations and in vivo 
stability1. Nanoparticles by virtue of their unique 
physicochemical properties such as ultra small size, large 
surface area to mass ratio etc can be used to overcome 
the limitations of conventional drug delivery systems7. 
Therefore the development and fabrication of 
nanoparticles have reported the following advantages 
over conventional systems: 
 Protection of drugs from gastric environment 
degradation 
 Targeted drug delivery 
 Prevention of first pass metabolism 
 Increased bioavailability and longer circulating time 
due to special absorptive mechanisms such as 
endocytosis 
 Controlled release of the drug 
 Minimized  plasma fluctuations and side effects 
 Easy penetration and absorption through tissues and 
cells 
 Enhanced  performance of drugs that are unable to 
pass clinical trials  
 Carrier for challenging drugs for diseases such as 
Cancer, HIV, diabetes etc. 
 Improved acceptability of dosage form by increased 
efficacy, safety, patient adherence and reduced 
health care costs1. 
Properties of Nanoparticles 
In pharmaceutics, ~90% of all medicines, the active 
ingredient is in the form of solid particles. The evolution 
of nanotechnology made it possible to produce drug 
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nanoparticles that can increase drug efficacy and reduce 
side effects by utilizing the new drug delivery pathways. 
1. Nanoparticle size: 
Size matching is an important parameter in carrying 
out the activity. The basic unit of the biological 
processes is the cell and the biochemical reactions inside 
it. It is believed that to treat the nanometer scaled 
component cells of human cells, nanoparticles drug 
delivery, which aims at influencing the cellular process, 
is of much interest. 
2. Nanoparticle surface: 
As the particle size decreases, the number of 
molecules present on the particle surface increases. For a 
spherical solid particle of diameter d and the molecular 
diameter is σ, then the percentage of molecules on the 
surface monolayer is given as 
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  For a 10µm particle sized material, a very small 
percentage of molecules are present on the surface. 
Hence, the dissolution rate is much lower for the 
microparticles than the nanoparticles. Lamprecht et al8 
observed adhesion of polystyrene particle to inflamed 
colonic mucosa, with the deposition 5.2%, 9.1%, and 
14.5% for 10-mm, 1000-nm, and 100-nm particles, 
respectively which shows that nanoparticle can show 
strong adhesion because of the increased contact area for 
van der Waals attraction. 
3. Nanoparticle suspension and settling: 
Since the particle size of the nanoparticle is small, 
the gravitational force is smaller on it so they can be 
easily suspended in a liquid. The particle settling velocity 
v, is given by stokes law as 
    v = 
𝑑2𝑔  (𝜌𝑠−𝜌 𝑙)
18𝜇 𝑙
 
      2 
where g is the gravitation acceleration (9.8 m/sec), ρl is 
liquid density (997 kg/m3 for water at 25°C), µl is 
viscosity. 
Brownian fluctuations resist the particle settlement. 
According to Einstein’s fluctuation –dissipation theory, 
average Brownian displacement x in time t is given as   
    x = 
2𝑘𝑏𝑇𝑡
𝜋𝜇𝑑
 
      3 
Where kb is the Boltzman constant (1.38 x 10
-23 J/K), and 
T is the temperature in Kelvin. 
For nanoparticles the gravitational pull is not stronger 
than the random thermal motion of the particles. Hence 
nanoparticles do not settle which provides a long shelf- 
life. 
4. Magnetic and optical properties 
Small nanoparticles exhibit unique magnetic and 
optical properties. For example, ferromagnetic materials 
become superparamagnetic below about 20 nm, i.e., the 
particles do not retain the magnetization because of the 
lack of magnetic domains.Such materials are useful for 
targeted delivery of drug and heat. For example, 
interaction of electromagnetic pulses with nanoparticles 
can be utilized for enhancement of drug delivery in solid 
tumors9. The particles can be attached to antibodies 
directed against antigens in tumor vasculature and 
selectively delivered to tumor blood vessel walls.  
Gold and silver nanoparticles show size-dependent 
optical properties10. The intrinsic color of nanoparticles 
changes with size because of surface plasmon resonance. 
Such nanoparticles are useful for molecular sensing, 
diagnostic, and imaging applications. 
5. Hydrophobicity 
It gives the extent and type of hydrophobic 
interactions of nanoparticulates with blood components 
and determines their bio fate .It also plays a role in drug 
release profile by impacting the degradation kinetics of 
polymeric shell11. It can be evaluated by methods such as 
hydrophobic interaction chromatography, two phase 
partition, contact angle measurement etc12. 
6. Crystallinity  
It affects the solubility and dissolution 
characteristics of the drug. In case of polymeric 
nanoparticles, degradation first occurs in amorphous 
regions followed by a slow rate in crystalline regions. 
Therefore it affects degradation rate and drug release 
kinetics11. 
7. Drug loading 
High drug loading capacity of a system reduces the 
quantity of matrix materials for administration. It can be 
done either by incorporation at the time of nanoparticle 
production or by absorption by incubation of carrier with 
concentrated drug solution after nanoparticle production. 
It depends upon the solid state solubility of drug in the 
matrix or polymer used which in turn depends upon the 
composition, molecular weight, interactions and end 
functional groups of the polymer
5
. 
8. Drug release 
Drug release and polymer biodegradation are 
important considerations for a nanoparticulate drug 
delivery system. Release rate depends upon factors such 
as drug solubility, surface bound/ adsorbed drug 
desorption, drug diffusion through matrix, erosion/ 
degradation of the matrix and combination of 
erosion/diffusion process5. 
Types of Nanoparticles
13 
Different types of nanoparticles along with description, 
materials used and applications are shown in below table 
1.
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Table 1: Different Types of Nanoparticles 
S.N. 
Type of 
Nanoparticle 
Description Materials used Applications Ref 
1. Lipid Based 
Submicron particles 
made of oily lipid core 
surrounded by soli or 
semi solid shell 
Phospholipids, 
triglycerides and 
cholesterol 
Systemic gene delivery, transdermal 
delivery of high molecular weight 
and poorly soluble drugs, drug 
delivery to lungs by nebulization 
14 
2. 
Polymeric 
Micelles 
based 
Formed by association 
of amphiphilic 
surfactants or polymeric 
molecules 
spontaneously in 
aqueous medium as 
core shell structures or 
vesicles 
Amphiphilic block 
copolymers, such as 
poly(ethylene oxide)-
poly(_-benzyl-
Laspartate) 
and poly(N-
isopropylacrylamide)-
polystyrene, 
Targeted delivery of 
chemotherapeutics, sustained release 
, parenteral delivery 
15, 16 
3. 
Polymer 
Based 
Colloidal solid particles 
with a size range of 10-
1000 nm which can be 
spherical, branched or 
shell structures 
Polymers such as 
chitosan, alginate 
gelatin, polyacrylates 
Increased uptake by immune cells, 
targeting of anti cancer drug to liver, 
oral delivery of insulin, brain 
targeting for neurodegenerative 
disorders 
17-19 
a. Hydrogels 
Association of 
hydrophobic moieties 
with soluble 
macromolecules 
Collagen, Gelatin, 
Starch,  Poly(n-vinyl 
pyrrolidine), 
Methacrylates, 
Poly(vinyl alcohol) 
Encapsulation and delivery of 
proteins, antigens and anti cancer 
agents 
20, 21 
b. Dendrimers 
Nanostructures highly 
branched with an inner 
core, size range is 1-100 
nm but mostly less than 
10 nm 
Macromolecules such 
as polyamidoamine 
(PAMAM), 
polypropyleneimine 
and polyaryl ether 
Attachment of drug molecules and 
targeting groups, coating agent 
protecting drugs, DNA delivery, 
diagnostic utilization for cancer 
treatment 
22, 23 
c. 
Calcium 
carbonate 
based 
Incorporation of drug 
into solid calcium 
carbonate 
Calcium carbonate Sustained release of drugs 24 
d. 
Protamine 
based 
Composed of 
protamine, a peptide 
associated with DNA or 
therapeutic agents 
Protamine- non 
antigenic, non toxic 
peptide 
DNA and oligonucleotide delivery 25 
e. 
Chitosan 
based 
Composed of chitosan, 
a biocompatible 
polymer associated with 
therapeutic agents 
Chitosan- polycationic 
polymer compring of d-
glucosamine and N-
acetyl-dglucosamine 
linked by b-(1,4)-
glycosidic bonds 
Carriers for gene delivery, ocular 
drug delivery 
26 
f. 
Silicone 
nanopore 
membrane 
Based 
Nanopore membranes 
which consist of arrays 
of parallel rectangular 
channels of 7-50 nm 
 
Increase stability of proteins which 
are unstable in aqueous solution at 
body temperature 
27 
g. 
Polymeric 
nanocapsules 
Spherical hollow 
structures in which drug 
is confined to a cavity 
and surrounded by 
poymer membrane 
poloxamer, PEG 400, 
polysorbate 80, 
propylene 
glycol, and citric acid 
Confined reaction vessels, protective 
shell for cells or enzymes, 
transfection vectors in gene therapy, 
dye dispersants, carriers in 
heterogenous catalysis, imaging and 
drug carrier 
28, 29 
 
 
Production of Nanoparticles 
Developing the nanoparticles of size range 
<100nm will help in exhibiting some unique physical 
and biological properties. But inorder to achieve 
nanoparticles of size range <100nm is possible with hard 
materials rather than using soft materials like drug and 
polymer. 
For hard materials, such as silica, metal oxides, 
and diamonds with melting points above 1000°C, 
nanoparticles are prepared in the size range of 1–100nm. 
For drugs that are usually soft materials with melting 
point below 300°C particles in the 1–100nm size range 
are more difficult to prepare, so they are prepared at 
<300nm size. 
To obtain nanoparticles in the 50–300nm range, 
for soft materials, for drug delivery, one requires of the 
order of 104–108 molecules in each particle. This size has 
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to be achieved from either solution phase (single 
molecule) or millimeter-size particle (1018 molecules).  
The two general approaches for the production of drug 
nanoparticles are 
a.  The particle is broken down to nano size,  
b. The particle will be built up from molecules. 
Manufacturing techniques of Nanoparticles 
Milling and Homogenization Techniques: 
There are specific and non specific approaches 
for the improvement of solubility and bioavailability. 
Specific approaches can only be applied to certain drug 
molecules i.e., with in case of cyclodextrins (CDs) to 
molecules that fit into the respective CD ring. Whereas, 
the nonspecific formulation approaches are applicable to 
almost any drug molecule. Such a nonspecific 
formulation approach since many years is micronization, 
which means converting relatively coarse drug particles 
to micrometer crystals with a mean diameter in the range 
of approximately 2–5 µm, and a corresponding size 
distribution approximately between 0.1 and 20 µm30. 
Here, the increase in the surface area leads to an increase 
in the dissolution velocity. That means micronization is a 
formulation approach to overcome the bioavailability 
problems of drugs of the biopharmaceutical specification 
class II (BSC II), where the rate limiting step is a too low 
dissolution velocity.  
Nowadays however, many of the new compounds are so 
poorly soluble that micronization is not sufficient to 
overcome a too low oral bioavailability. Consequently, 
the next step taken was to move from micronization to 
nanonization, which leads to further increase in surface 
area and thus there is an increase in dissolution velocity. 
Even highly water-sensitive drugs can be reduced to drug 
nanocrystals, even stored in the form of an aqueous 
nanosuspension (drug nanocrystals dispersed in aqueous 
surfactant/stabilizer medium). Drug nanocrystals can be 
produced by bottom-up or topdown technologies. In the 
case of bottom-up technologies, one starts with the 
molecules in solution and moves via association of these 
molecules to the formation of solid particles, i.e., it is a 
classical precipitation process31. In the case of top-down 
technologies, one starts with a coarse material and 
applies forces to disintegrate into the nanosize range. The 
diminution technologies can be categorized into two 
principal classes: 
1. Pearl/ball milling. 
2. High-pressure homogenization, and other 
processes. 
1. Pearl/ball-milling technology for the production of 
drug nanocrystal: 
Traditional equipment like Jet milling leads to a 
drug powder with a size range of roughly between 0.1 
and 20 mm, containing only a very small fraction of 
about 10% in the nanometer range[30]. Hence the 
traditional equipments used for micronization of drug 
powders such as rotor–stator colloid mills (Netzsch) or 
jet mills (Retsch) are of limited use for the production of 
nanocrystals.  
When a pearl mill is run over a sufficiently long 
milling time, drug nanosuspensions can be obtained. 
These mills consist of a milling container filled with fine 
milling pearls or larger-sized balls. The container can be 
static and the milling material is moved by a stirrer; 
alternatively, the complete container is moved in a 
complex movement leading consequently to movement 
of the milling pearls. Surfactants or stabilizers have to be 
added for the physical stability of the produced 
nanosuspensions. In the production process the coarse 
drug powder is dispersed by high-speed stirring in a 
surfactant/stabilizer solution to yield a macrosuspension. 
The choice of surfactants and stabilizers depends on the 
properties of the particles to be suspended and on the 
physical principles (electrostatic and steric stabilization) 
and the route of administration. 
Steric stabilization is recommended as the first 
choice because it is less susceptible to electrolytes in the 
gut or blood. Electrolytes reduce the zeta potential and 
subsequently impair the physical stability, especially of 
ionic surfactants. In many cases an optimal approach is 
the combination of a steric stabilizer with an ionic 
surfactant, i.e., the combination of steric and electrostatic 
stabilization. Adsorption onto the particle surface leads 
to high zeta potential values providing good physical 
stabilities.  
In case of parenteral drug nanocrystals, the 
choice is limited; for eg. For intravenous injection, 
accepted are lecithins, Poloxamer 188, Tween1 80, low 
molecular weight polyvinylpyrrolidone (PVP), sodium 
glycocholate (in combination with lecithin).  
Production of parenteral drug nanosuspension using 
pearl mills is much more tedious compared to producing 
oral drug nanosuspensions. The equipment needs to be 
sterilized and the product needs to be separated from the 
milling pearls by a preferentially aseptic separation 
process. 
One advantage of the pearl mills, apart from being low-
cost products, is their ability for scaling up. 
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Figure 1: Schematic view of a bed mill using recirculation method32 DISPERMAT® SL 
 
2. Drug Nanocrystals produced by High- Pressure 
Homogenization 
High-pressure homogenization has been applied 
for many years in various areas for the production of 
emulsions and suspensions and is currently used in food 
industry like homogenization of milk. A distinct 
advantage of this technology is its ease for scaling up, 
even to very large volumes. In the pharmaceutical 
industry parenteral emulsions are produced by this 
technology. 
Most of the homogenizers used are based on the 
piston-gap principle; an alternative is the jetstream 
technology. The Microfluidizer is based on the jet-stream 
principle. Two streams of liquid collide, diminution of 
droplets or crystals is achieved mainly by particle 
collision, but occurrence of cavitation is also 
considered.The Microfluidizer has also been described 
for the production of drug nanosuspensions; and requires 
10-50 cycles 33. 
The Microfluidizer can be used for the production of 
drug nanosuspensions in the case of soft drugs. In the 
case of harder drugs, a larger fraction of particles in the 
micrometer range remain, which do not exhibit the 
increase in saturation solubility because of their too large 
size. 
For many years cavitation was considered as the 
major force leading to particle diminution in the high-
pressure homogenization process. So, mostly water was 
used as the dispersion medium. In the piston-gap 
homogenizer the liquid is forced through a tiny 
homogenization gap, typically in the size range of 5–20 
µm. According to the Bernoulli equation, the streaming 
velocity and dynamic pressure increase extremely, the 
static pressure in the gap falls below the vapor pressure 
of water at room temperature. 
A liquid boils when its vapor pressure is equal to the 
static pressure, which means water starts boiling in the 
gap at room temperature leading to the formation of gas 
bubbles. The formation of gas bubbles leads to pressure 
waves disrupting oil droplets or disintegrating crystals. 
When leaving the homogenization gap, the static 
pressure increases to normal air pressure, which means 
the water does not boil anymore and the gas bubbles 
collapse. Collapsing of the gas bubbles (implosion) leads 
again to shock waves contributing to diminution. 
At the end of the 1990s it was found that similar 
efficient particle diminution can be achieved by 
homogenization in nonaqueous media such as oils and 
liquid polyethylene glycols. Preparation of drug 
nanocrystals in PEGs or oils leads to nanosuspensions 
that can directly be filled into capsules34,35. It is also 
possible to homogenize in melted nonaqueous matrices, 
which are solid at room temperature. Solidification of 
such a matrix leads to a fixation of drug nanocrystals in 
the solid matrix, thus minimizing or avoiding crystal 
contact and subsequent crystal fusion/growth. 
Preparation of drug nanosuspensions in water–
ethanol mixtures is favorable for producing dry products, 
because later the spray drying can be performed under 
milder conditions when using such a mixture. 
Homogenization in water–glycerol mixtures (2.25% of 
water-free glycerol) leads to isotonic drug 
nanosuspensions for parenteral administration. 
3. Production of Drug Nanocrystal Compounds by 
Spray-Drying: 
For the production of tablets, an aqueous 
nanosuspension can be used as granulation fluid. Starting 
from an aqueous macrosuspension containing the 
original coarse drug powder, surfactant, and water-
soluble excipient, the homogenization process can be 
performed in an easy one step yielding a fine aqueous 
nanosuspension. In a subsequent step the water has to be 
removed from the suspension to obtain a dry powder. 
One method of removing the water from the formulation 
is freeze drying, but it is complex and cost-intensive 
leading to a highly sensitive product36,37 and another 
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method is spray drying, which is simple and most 
suitable method for industrial production. 
The drug nanosuspension can directly be 
produced by high-pressure homogenization in aqueous 
solutions of water-soluble matrix materials. Afterward 
the aqueous drug nanosuspension can be spray dried 
under adequate conditions; the resulting dry powder is 
composed of drug nanocrystals embedded in a water-
soluble matrix38. 
One aim of a solid nanoparticulate system is 
releasing the drug nanocrystals after administration in the 
gastrointestinal tract (GI) as a fine nonaggregated 
suspension; the other is to increase the physical stability 
for long-term storage. 
Production in hot-melted matrices: 
A further possibility for the production of drug 
nanocrystals in solid matrices is high-pressure 
homogenization in hot melts. It offers advantages over 
production in aqueous solution and subsequent spray 
drying. The process is completely anhydrous, avoiding 
possible drug degradation or instabilities. The production 
can directly be performed by hot high pressure 
homogenization in melted material39,40. The 
homogenizers Micron Lab 40, batch and continuous, 
were equipped with temperature control jackets placed 
around the sample/product containers. Working 
temperatures up to 100°C (heated with water) or higher 
(heated with silicon oil) can be selected depending on the 
melting temperature of the used matrix material. For 
batch operation, solidification has to be averted between 
each homogenizing cycle. For homogenizers working in 
the continuous mode, the product containers must be also 
heated. 
As the first production step, a presuspension has 
to be formed consisting of a melted matrix with the 
addition of the drug powder and surfactant. In the 
following production step, the hot presuspension can be 
directly homogenized in the temperature-controlled 
homogenizer. After reaching the envisaged particle size 
and size distribution, the suspension can be solidified at 
room temperature by applying controlled cooling. 
Subsequently, the solid nanodispersions obtained can be 
processed to granulate by milling, for filling capsules or 
tablet compaction. Alternatively, the hot melt can 
directly be filled into hard gelatine or hydroxypropyl 
methylcellulose (HPMC) capsules. The absence of water 
during the whole production process as well as the short 
processing times and the one-step process to the final 
product are especially to be noted using the hot melt 
method. 
Pelletization Technique: 
The most commonly used pelletization 
techniques are the extrusion–spheronization and the drug 
layering onto sugar spheres. Irrespective of the 
pelletization technique applied, a multiparticulate dosage 
form will be obtained. Multiparticulate dosage forms 
show a faster and more predictable gastric emptying and 
more uniform drug distribution in the GI tract with less 
inter- and intraindividual variability in bioavailability41. 
A broad distribution of the pellets in the gut lumen can 
enhance the complete redispersion of the nanoparticles 
from the final solid dosage form. 
1. Matrix pellet preparation 
Aqueous nanosuspensions can be mixed with 
matrix materials like MCC, lactose etc., Also the 
nanosuspension works as a binder and wetting fluid for 
the extrusion process42-45. Binders like gelatine, HPMC, 
chitosans, or other polymers can be added to the 
nanosuspension before the high-pressure 
homogenization, which simplifies the production 
process. Alternatively, they can be dispersed in the 
produced nanosuspension after the highpressure 
homogenization. The binders which are used are 
necessary for the extrusion process but they can also 
positively influence the properties of the nanosuspension 
or the nanoparticles. 
2. Pellet preparation by Nanosuspension Layering 
An alternative way to transfer a prior produced 
nanosuspension into a pellet formulation is the 
suspension layering onto sugar spheres46. The binders 
that are necessary for this process can also be added 
before the high-pressure homogenization process 
resulting in the improved nanosuspension properties.
 
 
Figure 2: Schematic Production of drug nanocrystal-loaded matrix cores 
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Supercritical fluid Technology: 
A fluid is supercritical when it is compressed beyond its critical pressure (Pc) and heated beyond its critical 
temperature (Tc). Super Critical Fluid (SCF) technology has emerged as an important technique for particle 
manufacturing. The critical constant values of different super critical solvents are shown in table 2 below. 
Table 2: Critical Constant for Various Supercritical Solvents 
SCF Tc(°C) Pc(bar) 
Ethylene 9.3 50.3 
Trifluoromethane (fluoroform) 25.9 47.5 
Chlorotrifluoromethane 28.9 39.2 
Ethane 32.3 48.8 
Carbon dioxide 31.1 73.7 
Dinitrogen monoxide (laughing gas) 36.5 72.6 
Sulfur hexafluoride 45.5 37.6 
Chlorodifluoromethane (HCFC 22; R 22) 96.4 49.1 
Propane 96.8 43.0 
Ammonia 132.4 112.7 
Dimethyl ether (wood ether) 126.8 52.4 
Trichlorofluoromethane (CFC 11, R 11) 198.0 44.1 
Isopropanol 235.2 47.6 
Cyclohexane 280.3  
Toluene 318.6 41.1 
Water 374.0 220.5 
 
Much attention has been given to supercritical 
carbon dioxide for pharmaceutical particle formation 
since it is nontoxic, inexpensive, and has mild critical 
temperature. Carbon dioxide due to its quadrupole 
moment it is a nonpolar molecule with a small polarity. 
Hence, nonpolar or light molecules (e.g., menthol, 
methanol, acetone, toluene, and hexanes) easily dissolve 
in CO2, whereas the polar or heavy molecules (e.g., 
griseofulvin, paclitaxel, tetracycline, and dexamethasone 
phosphate) have a very poor solubility.  
Three important factors that govern drug solubility in 
supercritical CO2 are 
 Vapor pressure of drug, 
 Drug–CO2 interaction 
 Density of CO2. 
 Drug vapor pressure is a function of temperature (T), 
and CO2 density is a function of pressure (P) and T. 
Studies reveal that solubility of pharmaceutical 
compounds is highly dependent on CO2 pressure. As the 
pressure is reduced, solubility decreases because of a 
reduction in the CO2 density, which is closely related to 
its solubility power47-50. At a high pressure, the drug can 
be dissolved in CO2 and if the pressure is reduced to 
ambient, the drug precipitates out as fine particles. The 
fast depressurization results in a very fast rate of 
precipitation providing small drug particles. This process 
is termed as rapid expansion of supercritical solution 
(RESS). Most of the drug particles produced by RESS 
have been in the 1–5 mm-size range. The rapid 
expansion of supercritical CO2 does produce nuclei 5–
10nm in diameter, but these nuclei grow because of 
coagulation and condensation to produce the final 
micrometer-size particle. 
Recently, Thakur and Gupta51 the challenges of 
RESS (low solubility and growth by coagulation) are 
overcomed by utilizing a cosolvent that is solid at the 
nozzle exit conditions. The solid cosolvent (SC) 
enhances the solubility in supercritical carbon dioxide 
and provides a barrier for coagulation in the expansion 
chamber. The SC is later removed from the solute 
particles by lyophilization (sublimation). The new 
process is termed as RESS–SC. The choice of a proper 
SC is the key for successful RESS-SC.  
Various requirements for the selection of the SC are 
 Good solubility in supercritical CO2 
 Solid at nozzle exit condition (5–30 °C) 
 Good vapor pressure for easy removal by 
sublimation 
 Should be nonreactive with drugs or CO2 
 Inexpensive. 
Menthol satisfies the requirements mentioned above. It 
has appreciable solubility in CO2 and can easily sublime 
under vacuum. 
Polymer or Protein Stabilized Nanoparticles from 
Emulsions 
Poorly water-soluble drugs have a challenge in 
their delivery. Such drugs can be given by nanoparticle 
delivery, which can avoid the allergic side effects due to 
the use of cremaphors (e.g., polyethyoxylated castor oil) 
in conventional formulations. However, for drugs with 
crystal forming habits, there is always the hazard of the 
formation of large microparticles (>10–15 mm) from 
aggregation/ bonding of nanoparticles; this can lead to 
infarction or blockage of the capillaries, resulting in 
ischemia or oxygen deprivation and possible tissue 
death. Hence, the nanoparticles need to be stabilized 
using biocompatible proteins (e.g., human serum 
albumin) or polymers (e.g., polylactide, 
polycaprolactone). 
Emulsification Solvent Evaporation process 
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In this process, polymers like poly(d,l-lactide- 
co-glycolide) (PLGA), poly(lactic acid) (PLA), 
polymethacrylate and the drug is mixed in a water-
immiscible solvent like methylene chloride, chloroform, 
ethyl acetate and is added dropwise to aqueous phase 
containing a surface stabilizer (e.g., polysorbate, 
polyvinyl alcohol, methyl cellulose, genatin, albumin, 
poloxomar)52,53. A high shear is provided using a 
homogenizer, which reduces the droplet size of the 
organic dispersed phase. The evaporation of solvent 
hardens the nanoparticles. Formed nanoparticles are 
harvested from the aqueous slurry by lyophilization. 
For the water-soluble drugs, a double-emulsion 
(water/oil/water) variation of the process is utilized. 
First, the drug is dissolved in water and then emulsified 
in water to obtain drug/ water as the dispersed phase and 
organic solvent as the continuous phase. Then, this 
emulsion is added to the large aqueous phase with 
emulsifier to create double emulsion. As the droplet size 
of the first emulsion needs to be much smaller than in the 
second outer emulsion, the emulsifier amount is much 
higher in the first emulsion than in the second emulsion. 
In emulsification, shear forces help create more surface 
and hence smaller droplet size emulsion, whereas the 
surface tension opposes the formation of more surface.  
If a smaller droplet size is desired, then high 
shear energy is needed. This energy requirement can be 
reduced if the surface tension is reduced which can be 
done by adding a surfactant or surface stabilizing agent 
such as albumin, poly vinyl alcohol (PVA), poly acrylic 
acid (Carbopol®), poly(oxyethylene-b-oxypropylene-b-
oxyethylene) (Poloxamer or Pluronic®). Both Carbopol 
and Poloxamer show mucoadhesive properties which 
may be beneficial in oral drug delivery applications. 
  Once the droplets are created, it is then 
important to solidify them to avoid coalescence. The 
final particle size is directly proportional to emulsion 
droplet size and the coalescence during hardening. For 
creating fine emulsion for obtaining nanoparticles, the 
use of a high amount of surface stabilizer is avoided to 
reduce the high load of the polymer exipients.  
Sonication 
Sonication generates emulsions through 
ultrasound-driven mechanical vibrations, which causes 
cavitation. Rarefaction and compression cycles of 
sonication create vapor bubbles, which grow with time. 
Once a critical size is achieved, the bubble collapses 
violently, releasing the energy creating hot spots and 
hydroxyl free radicals. The duration and intensity of 
sonication can be used to create varying emulsion droplet 
sizes. 
Homogenization 
Homogenization is similar to sonication based 
on emulsification efficiency, but is relatively more 
effective in emulsifying viscous solutions. Ambient 
pressure homogenizers use rotor–stator types of mixers, 
which can go to very high rotational speeds. High-
pressure homogenization uses high pressure to force the 
fluid into microchannels of a special configuration and 
initiates emulsification via a combined mechanism of 
cavitation, shear, and impact, exhibiting excellent 
emulsification efficiency. Sonication usually generates 
more heat, and hence is less suitable for heat-sensitive 
materials. Homogenization is generally more effective in 
making fine emulsions. Usually, multiple passes are 
needed to achieve the desired emulsion droplet size. The 
emulsion droplet size decreases with increasing 
homogenization intensity54. Using a rotor–stator 
homogenizer, the emulsion droplet size was found to be 
viscosity (µ) dependent and proportional to µ0.11 of the 
dispersed phase and µ-0.43 of the continuous phase. 
Nanoparticle Hardening 
Particle hardening due to solvent evaporation 
plays an important role in the growth of the particle 
during coalescence. The particle stickiness comes from 
the solvent associated with the polymer and drug. In the 
beginning of the process, the droplets are liquid and 
coalesce if they come any closer than about 1 nm. When 
part of the solvent is removed, the droplets are still 
sticky, but the particle bridging is slowed down owing to 
the increased viscosity of the drop interior. Once most of 
the solvent is removed, the particles become hard and 
now they can start to bounce off from other colliding 
particles. Wang and Schwendeman55 measured the 
removal rate of the solvent from particles with respect to 
time as shown in Figure 3. 
 
Figure 3: Methylene chloride removal profile from 
encapsulation of triamcinolone acetonide in PLGA 
particles
55. 
Initially, the solvent removal is fast, owing to 
the high diffusivity of solvent and the dissolution of the 
solvent in the aqueous media. With time the droplets 
become hard on the surface due to polymer precipitation, 
which slows down the solvent diffusion. due to polymer 
precipitation, which slows down the solvent diffusion. 
Particle growth continues as a result of coalescing for the 
duration in which the solvent is not completely removed 
to the point when particles are not sticky. 
Residual Solvent and Emulsifier 
Residual solvent in pharmaceutical 
preparations, including nanoparticles, is a growing 
concern because of the toxicological risks associated 
with such residuals. If proper evaporation and 
lyphilization is not carried out, then the final nanoparticle 
may retain the solvent. The interfacial PVA influences 
particle size, zeta potential, polydispersity index, surface 
hydrophobicity, and drug loading. Both residual solvent 
and emulsifier can be reduced by cross-flow 
microfiltration. Cross-flow microfiltration is particularly 
attractive for the processing of large volumes of 
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nanoparticulate suspension, as the membrane surface can 
be easily increased. Other methods such as evaporation 
under reduced pressure or ultracentrifugation usually 
only treat small batch volumes.  
Protein Stabilized Nanoparticles 
Owing to the concerns of residual emulsifier in 
the final product, several researchers have utilized 
albumin protein stabilizer because of its complete 
compatibility with even the injectable formulations. The 
choice of organic solvent and the extent of 
homogenization can be used for further variation, for 
example the aqueous phase was presaturated with the 
organic solvent and a small amount of ethanol was added 
to the organic phase. In this variation, smaller 
nanoparticles, 140–160 nm, are obtained. To form a solid 
and stable layer of albumin onto drug nanoparticles, the 
protein needs to be cross-linked (or denatured) onto the 
particle surface. Typically albumin crosslinking can be 
achieved by heat, use of cross-linker such as 
gluteraldehyde, or high shear. Fortunately, in the 
emulsification solvent evaporation process high shear is 
already in use, hence it can also be used for cross-linking 
protein stabilizers. High-shear cross-linking works for 
the protein-bearing sulfhydryl or disulfide groups (e.g. 
albumin). The high-shear conditions produce cavitation 
in the liquid, which causes tremendous local heating and 
results in the formation of hydroxyl radicals that are 
capable of cross-linking the polymer, for example, by 
oxidizing the sulfhydryl residues (and/or disrupting the 
existing disulfide bonds) to form new, cross-linking 
disulfide bonds56-58. 
Physical Characterization of Nanoparticles  
Sizing methods are frequently classified (shown 
in table 3 below) according to the manner in which they 
extract information from the sample. Counting methods, 
such as microscopy or single-particle optical sensing 
(SPOS), measure the size of individual particles to 
compile a histogram reflecting the overall distribution. 
 
Table 3: Physical characterization of Nanoparticles 
Sno. Property Analytical method(s) References 
1. Presence size  Dark field optical microscopy Size Dynamic light scattering, Static 
light scattering, Ultrasonic spectroscopy, Turbidimetry, NMR, 
Single particle optical sensing, FFF Hydrodynamic fractionation, 
Filtration 
59,60-66 
2. Morphology  TEM, SEM, Atomic force microscopy 67–75 
3. Surface charge  Electrophoretic light scattering, U-tube electrophoresis, 
Electrostatic-FFF  
64,76 -81 
4. Surface 
hydrophobicity 
Hydrophobic interaction chromatography 
76,71,82 
5. Surface adsorbates  Electrophoresis 70,83 
6. Density  Isopycnic centrifugation, sedimentation-FFF 70,84 
7. Interior structure  Freeze-fracture SEM, DSC, X-ray diffraction, NMR 75,77,85,86-88 
 
Dynamic Light Scattering 
DLS, also known as photon correlation 
spectroscopy (PCS) or quasi-elastic light scattering 
(QELS) records the variation in the intensity of scattered 
light on the microsecond time scale60,61. This variation 
results from interference of light scattered by individual 
particles under the influence of Brownian motion, and is 
quantified by compilation of an autocorrelation function. 
This function is fit to an exponential, or some 
combination or modification thereof, with the 
corresponding decay constant(s) being related to the 
diffusion coefficient(s). 
Static light Scattering/Fraunhofer Diffraction 
Static light scattering (SLS) is an ensemble 
method in which the pattern of light scattered from a 
solution of particles is collected and fit to fundamental 
electromagnetic equations in which size is the primary 
variable61,62. The method is fast and rugged, but requires 
more cleanliness than DLS. 
Acoustic Spectroscopy 
Acoustic spectroscopy measures the attenuation 
of sound waves as a means of determining size through 
the fitting of physically relevant equations63. 
Turbidimetry 
For nonabsorbing particles, turbidity is the 
complement to light scattering because it represents the 
amount of incident radiation not reaching a detector, that 
is, light lost to scattering64. 
 Nuclear Magnetic Resonance 
Nuclear magnetic resonance (NMR) can be used 
to determine both the size and the qualitative nature of 
nanoparticles. The selectivity afforded by chemical shift 
complements the sensitivity to molecular mobility to 
provide information on the physicochemical status of 
components within the nanoparticle 65. 
Single-Particle optical Sensing 
A particle counting method, SPOS, which is 
also known as optical particle counting, involves 
recording the obscuration or scattering of a beam of light 
that results from the passage of individual particles 
through a sensor. Signal magnitude is translated to the 
size of the particle via use of a previously determined 
calibration curve using standards approximating the 
sample in terms of shape and optical properties. 
Electron Microscopy 
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Scanning and transmission electron microscopy, 
SEM and TEM, respectively, provide a way to directly 
observe nanoparticles. SEM is better for morphological 
examination67,68,77. TEM has a smaller size limit of 
detection, is a good validation for other 
methods,andaffords structural information via electron 
diffraction, but staining is usually required, and one must 
be cognizant of the statistically small sample size and the 
effect that vacuum can have on the particles. Very 
detailed images data can result from freeze-fracture 
approaches in which a cast is made of the original 
sample69,70. 
Atomic Force Microscopy 
In this technique, a probe tip with atomic scale 
sharpness is rastered across a sample to produce a 
topological map based on the forces at play between the 
tip and the surface. The probe can be dragged across the 
sample (contact mode), or allowed to hover just above 
(noncontact mode), with the exact nature of the particular 
force employed serving to distinguish among the 
subtechniques72,73. 
 Filtration 
A simple, yet effective, approach of determining 
particle size is filtration, in which the concentration of a 
suspension is determined before and after passage 
through filter membranes of various sizes. 
Field-Flow Fractionation 
The nature of the perpendicular force defines the 
type of field-flow fractionation (FFF) and thus the 
particle property on which separation occurs: 
sedimentation (buoyancy, size), flow (hydrodynamic 
size), electrostatic (charge), or thermal (diffusion)67. 
Hydrodynamic Chromatography 
In a sufficiently narrow channel of parabolic 
flow, particles of different size will on average 
experience different flow lines because of their 
differential ability to approach the channel wall. The 
particles will separate based on that property, with those 
that are smaller eluting later just as they would in flow-
FFF. 
Hydrophobic Interaction Chromatography 
In this method the analyte is first adsorbed onto 
a chromatographic stationary phase using a high 
concentration of an antichaotropic salt82. 
Electrophoresis 
This process will determine the clearance and 
biodistribution of the colloid, so evaluating the exact 
nature of the surface coverage is required to achieve a 
useful understanding. The small size of nanoparticles 
allows their electrophoretic behavior to be observed 
using bioanalytical tools such as isoelectric focusing and 
2-D polyacrylamide gel electrophoresis83. 
Isopycnic Centrifugation 
This self-focusing separation allows 
nanoparticle density to be determined, which along with 
particle size and bulk substituent concentration can in 
turn be used to calculate a number concentration70. 
Zeta Potential 
Zeta potential is used as a surrogate for surface 
change, and is often measured by observing the 
oscillations in signal that result from light scattered by 
particles located in an electric field. Doppler shift is 
generally used for this purpose.  
Scanning Probe Technique 
This technique uses the interaction between a 
sharp tip and a surface to obtain the image. The sharp tip 
is held very close to the surface to be examined and is 
scanned back and forth. As the tip is scanned across the 
sample, the displacement of the end of the cantilever is 
measured, using a laser beam. This can image insulating 
materials simply because the signal corresponds to the 
force between the tip and the sample, which reflects the 
topography being scanned2.   
Optical tweezers 
Optical tweezers use a single laser beam 
(focused by a high-quality microscope objective) to a 
spot on the specimen plane. The radiation pressure and 
gradient forces from the spot create an optical trap, which 
holds a particle at its center. Small interatomic forces and 
displacements can be measured by this technique. 
Samples that can be analyzed range from single atoms to 
micrometer-sized spheres to strands of DNA and living 
cells2.   
Challenges to Nanoparticulate drug delivery systems: 
The development of nanoparticulate drug delivery 
system requires understanding of both surface chemistry 
of nanomaterials as well as the interaction chemistry of 
these materials with the biological systems. The 
challenges can be due to biological, safety, 
manufacturing and financial issues89 
 Biological challenges- Problems such as rapid 
clearance by immune system, low targetting 
efficiency and difficulty in crossing barriers may be 
encountered. Knowledge of mechanism underlying 
the intracellular uptake, processing and fate of the 
nanoparticulate in the complex biological systems is 
needed. 
 Safety challenges- the negative impact of interaction 
between nanomaterials and biological systems is 
dealt in Nanotoxicology. Investigations have shown 
that toxicity has lead to several harmful effects on 
the biological systems90 have reported many 
evidences for nanotoxicology. Gold and polystyrene 
nanoparticles have caused hemolysis and blood 
clotting. Carbon nanotubes showed platelet 
aggregation91, oxidative stress, mitochondrial 
dysfunction92. Quantum dots have showed 
cytotoxicity by induction of reactive oxygen species 
causing damage to nucleus and mitochondria93,89 
suggested the establishment of proper standards and 
testing protocols for nanoparticulates. 
 Manufacturing challenges- Due to complexity in 
methods and high cost of materials employed, they 
may not be compatible with large scale production. 
Proper statistical approaches can be followed to 
improve the scale up for increased production and 
commercialization of nanoparticles. 
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 Economical challenges- Despite the number of 
patents, commercialization is a problem still due to 
high costs of development94. 
Emerging Trends in Nanoparticulate drug delivery 
systems: 
Nanotechnology offers great potential benefits 
for drug delivery and therapy of respiratory and  systemic 
diseases. Nanoparticles have been of significant interest 
for some time because they can be designed to 
simultaneously carry a drug payload, specifically target 
features of diseased tissues, and carry an imaging 
molecule to track drug accumulation and clearance in 
tissues. Moreover, they can be engineered to tailor drug 
delivery and improve pharmacokinetics. A variety of 
Nanoparticles have been investigated in experimental 
animal models as tools to improve the delivery and 
therapeutic efficacy of drugs or genes delivered to the 
lung or other organ systems. The emerging applications 
of nanoparticles shown in below table 4. 
 
Table 4: Emerging applications of Nanoparticles 
Emerging trend Application Ref 
Biological Analysis and 
Discovery 
Segregation of proteins and nucleic acids based on size and shape, 
sequencing of a genome and sum total of genes in an organism. 
95 
Nanoparticulate Tagging 
 
Attachment of nanoparticles such as quantum dots and nanowires  to 
molecules of interest are being used in detection technologies 
96 
Nanostructured materials  Used as portable biodetectors that can be used for detection of chemicals 
based on colour change  in hazardous environments 
96 
Single-Molecule Detection 
 
Nanostructures such as quantum dots that can emit a photon in presence of 
a particular molecule can be used 
97 
Protective Nanoparticles 
against pathogens  
By virtue of their physical nature, cause disruption of bacteria and viruses 
hence used as cream for lacing fabrics in hospitals 
96 
Nanotubes and Cellular 
Manipulations  
Removal and insertion of nucleus from one cell to another, cloning and 
making probes 
98 
Nanoengineered Prosthetics Replacement and implantation of organs 96 
Thiomer Nanoparticles Possess mucoadhesive, enzyme inhibitory and permenation enhancing 
properties, used in insulin and calcitonin systems 
99 
Nanostructured Monoliths Protein and peptide analysis based on nanocoupling technique 2 
Antibody coated Nanospheres  Targeted delivery of drugs 2 
Nanocrystallites Increased  solubility and bioavailability using pluronics 2 
Nanohybrids  Poorly soluble non ionic drug delivery, non viral vector for gene delivery  100,101 
Nanocontainer technology Versatile carriers used to evade immune system and for drug delivery 102 
Electrospun Nanofibers as  
Drug-Delivery Systems 
Complete release of poorly soluble drugs, 
 for buccal and topical uses 
103 
 
CONCLUSION 
Developments in the field of nanotechnology 
are very promising. Many of them are therapeutically in 
use and others are in various stages on preclinical and 
clinical development. Thus they are expected to have a 
tremendous impact on medicines for decades to come. 
The understanding of properties of nanoparticles shows 
unique characteristics such as increased surface area, 
ease of suspension, magnetic and optical properties and 
high drug loading. Using recent technologies of 
production they can be used for any types of drugs. 
Their characterization uses various techniques to 
determine physiologically relevant parameters. The 
value of nanotechnology enabled compounds is expected 
to reach $ 220 billion by 2015. Therefore the use of 
nanoparticles will transform medical treatment by 
targeting the drugs to specific areas of the body without 
side effects or toxicity concerns since lower doses can be 
used. Therefore further advances in this field would turn 
it into the next generation of drug delivery system. 
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